GENFIT Stock Euronext Paris
Stocks
FR0004163111
Biotechnology & Medical Research
OTC Markets Traded|
End-of-day quote
Euronext Paris
|
||
| - EUR | - |
|
| 07-03 | Genfit soars on news of U.S. reimbursement for a product |  |
| 07-03 | Genfit's Liver Disease Blood Test Approved for US Medicare Reimbursement | MT |
| Market Cap | 689M 800M 648M 592M 1.11B 75.64B 1.11B 7.66B 2.97B 38.78B 3.01B 2.94B 125B | P/E 2026 * |
35.6x | P/E 2027 * | 91.5x |
|---|---|---|---|---|---|
| Enterprise Value | 638M 741M 600M 548M 1.03B 70.03B 1.03B 7.09B 2.75B 35.91B 2.78B 2.72B 116B | EV / Sales 2026 * |
6.37x | EV / Sales 2027 * | 5.02x |
| Free-Float |
86.89% | Yield 2026 * |
-
| Yield 2027 * | - |
| Manager | Title | Age | Since |
|---|---|---|---|
Pascal Prigent
CEO | Chief Executive Officer | 58 | 2019-09-15 |
Thomas Baetz
DFI | Director of Finance/CFO | 52 | 2021-04-21 |
Pejvack Motlagh
CTO | Chief Tech/Sci/R&D Officer | - | 2025-11-26 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | 2017-06-15 | |
| Director/Board Member | 54 | 1999-09-14 | |
| Director/Board Member | 58 | 2017-06-15 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.54% | -2.84% | -1.90% | +14.52% | 48.93B | |
| -0.40% | +1.03% | +439.20% | +499.20% | 45.01B | |
| -1.42% | +2.30% | +45.46% | +19.36% | 44.07B | |
| -1.22% | -2.31% | +12.40% | +71.48% | 40.73B | |
| +0.53% | -1.36% | +16.04% | +48.23% | 33.52B | |
| -0.21% | +9.14% | - | - | 17.77B | |
| -0.35% | -1.56% | +22.59% | +116.19% | 16.5B | |
| -1.01% | +0.50% | +15.83% | +27.98% | 14.67B | |
| -1.65% | -1.03% | +77.75% | +37.63% | 13.77B | |
| Average | -0.92% | +0.53% | +78.42% | +104.33% | 30.55B | |
| Weighted average by Cap. | -1.03% | +0.11% | +94.86% | +122.11% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 100M 116M 94.19M 86.04M 161M 10.99B 162M 1.11B 432M 5.64B 437M 427M 18.18B | 124M 144M 117M 107M 199M 13.61B 200M 1.38B 535M 6.98B 541M 529M 22.51B |
| Net income | 22.88M 26.57M 21.51M 19.65M 36.76M 2.51B 36.88M 254M 98.69M 1.29B 99.76M 97.56M 4.15B | 6.8M 7.9M 6.39M 5.84M 10.93M 746M 10.96M 75.55M 29.33M 383M 29.65M 29M 1.23B |
| Net Debt | -51.12M -59.36M -48.06M -43.9M -82.14M -5.61B -82.41M -568M -221M -2.88B -223M -218M -9.28B | -66.17M -76.84M -62.21M -56.83M -106M -7.26B -107M -735M -285M -3.72B -289M -282M -12.01B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
